Skip to main content
Donald M. Cannon
( out of 113 reviews )

Donald M. Cannon, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
Salt Lake City
801-581-2396
  • Donald Cannon, MD, is an Assistant Professor in the Department of Radiation Oncology at the University of Utah. He is a member of the multidisciplinary team specializing in the treatment of tumors of the central nervous system (brain, spinal cord, and skull base) and provides specialty care for patients with cancers of the skin, breast, and genitourinary system.

    Dr. Cannon received his medical degree at Weill Cornell Medical College in New York, NY, followed by a residency in radiation oncology at the University of Wisconsin where he was a chief resident from 2012 to 2013. He is a member of the American Society for Therapeutic Radiology and Oncology and American Brachytherapy Society. Originally from Utah, he enjoys the outdoors and spending time with his family. He feels passionately about providing optimal care to his patients and involving them in the decision-making process.

    Patient Rating

    4.9 /5
    ( out of 113 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 30, 2024
    HUNTSMAN CANCER CENTER

    He is awesome. He made me feel at ease. He was easy to talk to. He listened attentively to my questions and explained the process very clearly.

    September 21, 2024
    HUNTSMAN CANCER CENTER

    thank you for saving my life

    September 19, 2024
    HUNTSMAN CANCER CENTER

    Dr. Cannon is in our opinion the people person that we have worked with. Keep it up.

    September 08, 2024
    HUNTSMAN CANCER CENTER

    I would recommend Dr D Cannon to anyone facing cancer treatment.

    September 08, 2024
    HUNTSMAN CANCER CENTER

    Very good caring Doctor !! Excellent care!!

    July 17, 2024
    FARMINGTON HEALTH CENTER

    I can't say enough about what a caring professional person that he is. He really cares and is a master of what he does. I trust him with my life. Amazing person.

    July 17, 2024
    FARMINGTON HEALTH CENTER

    Dr. Cannon best ever! A good friend also.

    July 09, 2024
    HUNTSMAN CANCER CENTER

    Dr Cannon was professional, kind and respectful. He took his time and did not rush thru appt.

    July 04, 2024
    FARMINGTON HEALTH CENTER

    Dr. Cannon has been great. He takes the time to explain your treatment in detail.

  • Donald Cannon, MD, is an Assistant Professor in the Department of Radiation Oncology at the University of Utah. He is a member of the multidisciplinary team specializing in the treatment of tumors of the central nervous system (brain, spinal cord, and skull base) and provides specialty care for patients with cancers of the skin, breast, and genitourinary system.

    Dr. Cannon received his medical degree at Weill Cornell Medical College in New York, NY, followed by a residency in radiation oncology at the University of Wisconsin where he was a chief resident from 2012 to 2013. He is a member of the American Society for Therapeutic Radiology and Oncology and American Brachytherapy Society. Originally from Utah, he enjoys the outdoors and spending time with his family. He feels passionately about providing optimal care to his patients and involving them in the decision-making process.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Primary

    Education history

    Chief Resident Radiation Oncology - University of Wisconsin Hospital & Clinics Chief Resident
    Radiation Oncology - University of Wisconsin Hospital & Clinics Resident
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Medicine - Weill Cornell Medical College M.D.
    Undergraduate Major: Physics; Minor: Mathematics - Brigham Young University B.S.

    Selected Publications

    Journal Article

    1. Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles T, Cannon DM, Haaland B, Schroeder JD, Nix D, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S (2023). Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis. Res Sq, rs.3.rs-2997157.
    2. Okwundu N, Weil CR, Soares HP, Fine GC, Cannon DM (2023). Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases. Front Nucl Med, 3.
    3. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S (2023). NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw, 21(1), 12-20.
    4. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. (Read full article)
    5. Kundu B, Brock AA, Garry JG, Jensen RL, Burt LM, Cannon DM, Shrieve DC, Rolston JD (2022). Outcomes using linear accelerator stereotactic radiosurgery for the treatment of trigeminal neuralgia: A single-center, retrospective study. Surg Neurol Int, 13, 246. (Read full article)
    6. Kraus RD, Weil CR, Frances Su FC, Cannon DM, Burt LM, Mendez JS (2022). Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients. Neurooncol Pract, 9(5), 380-389. (Read full article)
    7. Peterson JS, Peckham ME, Poppe MM, Burt LS, Shrieve DC, Cannon DM (2022). Delineating the Subarachnoid Space in the Adult Lumbosacral Spine Using Computed Tomographic Myelography: An Aid for Clinical Target Volume Delineation in Craniospinal Irradiation. Adv Radiat Oncol, 7(5), 100994. (Read full article)
    8. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2022). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614.
    9. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2021). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614. (Read full article)
    10. Peterson JS, Peckham ME, Poppe MM, Burt LS, Shrieve DC, Cannon DM (IN SUBMISSION). Delineating the Sub-Arachnoid Space in the Adult Lumbosacral Spine Using CT Myelography: An Aid for Clinical Target Volume Delineation in Craniospinal Irradiation. Adv Radiat Oncol.
    11. Kraus RD, Weil CR, Wells S, Tward JD, Groundland JS, Jones KB, Cannon DM (2021). Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens? Adv Radiat Oncol, 7(2), 100795. (Read full article)
    12. Parsons MW, Whipple NW, Poppe MM, Mendez JS, Cannon DM, Burt LM (2021). The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. J Neurooncol, 151(2), 93-101.
    13. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5. (Read full article)
    14. Ager BJ, Torgeson A, Francis SR, Burt LM, Gaffney DK, Cannon DM (2019). Impact of Brachytherapy Boost and Dose-escalated External Beam Radiotherapy in Margin Positive Cervical Cancer Treated With Chemotherapy and Radiation. Am J Clin Oncol, 43(1), 35-42. (Read full article)
    15. Cannon RB, Kull AJ, Carpenter PS, Francis S, Buchmann LO, Monroe MM, Lloyd S, Hitchcock YJ, Cannon D, Weis JR, Houlton JJ, Hunt JP (2019). Adjuvant radiation for positive margins in adult head and neck sarcomas is associated with improved survival: Analysis of the National Cancer Database. Head Neck, 41(6), 1873-1879. (Read full article)
    16. Torrecillas V, Shepherd HM, Francis S, Buchmann LO, Monroe MM, Lloyd S, Cannon D, Hitchcock YJ, Weis JR, Hunt JP, Houlton JJ, Cannon RB (2018 Oct). Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. Oral Oncol, 85, 1-7.
    17. Lippert D, Dang P, Cannon D, Harari PM, McCulloch TM, Hoffman MR, Hartig GK (9/2017). Lymph Node Yield in Therapeutic Neck Dissection: Impact of Dissection Levels and Prior Radiotherapy. Ann Otol Rhinol Laryngol.
    18. Morris ZS, Cannon DM, Morris BA, Bentzen SM, Kozak KR (2015). Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer. J Thorac Oncol, 10(11), 1608-15. (Read full article)
    19. Cannon DM, Mohindra P, Gondi V, Kruser TJ, Kozak KR (2015). Choroid plexus tumor epidemiology and outcomes: implications for surgical and radiotherapeutic management. J Neurooncol, 121(1), 151-7. (Read full article)
    20. Cannon DM, Geye HM, Hartig GK, Traynor AM, Hoang T, McCulloch TM, Wiederholt PA, Chappell RJ, Harari PM (2014). Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck, 36(8), 1120-5. (Read full article)
    21. Cannon DM, Kruser TJ, Khuntia D (2011). Principles and Application of PET in Brain Tumors. PET Clin, 6(2), 131-48. (Read full article)

    Review

    1. Parsons MW, Whipple NS, Poppe MM, Mendez JS, Cannon DM, Burt LM (2020). The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. [Review]. J Neurooncol, 151(2), 93-101. (Read full article)

    Abstract

    1. Lew F, Weil CR, Rock CB, Rock CB, Burt LM, Decesaris C, Jensen RL, Shrieve DC, Cannon DM (2022). Effects of Expansion Size from Gross Tumor Volume to Planning Target Volume on Control Rates and Patterns of Recurrence in Conventionally Fractionated Radiotherapy for WHO Grade I Meningiomas [Abstract]. 114(3), e45-e46.
    2. Weil CR, Rock CR, Vikren S, Gravbrot Ni, Lew FH, Rock CB, Burt LM, DeCesaris CM, Jensen RJ, Shrieve DC, Cannon DM (2022). Effects of expansion size from gross tumor volume (GTV) to planning target volume (PTV) on control rates and patterns of recurrence in conventionally fractionated radiotherapy for WHO grade 1 meningiomas [Abstract].